Atossa Therapeutics – Developing Innovative Therapies To Address Unmet Needs In Breast Cancer
Dr. Steven Quay, Chairman of the Board and CEO of Atossa Therapeutics, a company focused on preventing breast cancer in at-risk women and treating breast cancer in women of all ages, discusses the development of a drug called (z)-endoxifen for breast cancer treatment which is currently undergoing 3 separate phase 2 clinical trials in the US.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Cancer. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Cancer and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Cancer?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Key Takeaways
- Key Point: Steven Quay, Chairman of the Board and CEO of Atossa Therapeutics, a company focused on preventing breast cancer in at-risk women and treating breast cancer in women of all ages…
- Key Point: Steven Quay is the founder of Seattle-based Atossa Therapeutics Inc.
- Key Point: (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions.
- Key Point: from The University of Michigan, was a postdoctoral fellow at MIT with Nobel Laureate H.
- Key Point: Gobind Khorana, a resident at the Harvard-MGH Hospital, and was on the faculty of Stanford University School of Medicine.
Steven Quay is the founder of Seattle-based Atossa Therapeutics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions.
He received his M.D. and Ph.D. from The University of Michigan, was a postdoctoral fellow at MIT with Nobel Laureate H. Gobind Khorana, a resident at the Harvard-MGH Hospital, and was on the faculty of Stanford University School of Medicine. His contributions to medicine have been cited over 9,600 times.
He has founded six startups, invented seven FDA-approved pharmaceuticals, and holds 87 US patents. Over 80 million people have benefited from the medicines he invented.
His current passion is the prevention of the two million yearly breast cancer cases worldwide.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.



